The global oral solid dosage contract manufacturing market size is expected to reach $54.7B by 2030, registering a CAGR of 6.0% over the forecast period, according to a report by Research & Markets.
Increasing complexity of new drug molecules, R&D investments by large Contract Manufacturing Organizations (CMOs) & Contract Development & Manufacturing Organization (CDMOs), and rising demand for new therapies would drive the growth of the market.
Oral solids are the most widely accepted dosage forms in the pharmaceutical sector as they are cost-effective, simple to manufacture, and patient-friendly. Furthermore, advances in drug delivery technology, such as the delivery of drugs and sustained release formation, are enabling oral solids to achieve even higher levels of bioavailability while lowering drug administration frequency.
The global market is growing in conjunction with the oncology sector. Clinical-stage cancer programs increased by 77% between 2015 and 2020 (1,642 to 2,911) and completely dominate the landscape, resulting in approximately one-quarter of drugs currently being developed globally being classified as highly potent. This tendency forward into high potency is having a significant impact on the CDMO space, as the increasing demand for smaller-scale and encapsulated manufacturing processes presents a challenge for most of pharma's installed capacity. The COVID-19 crisis has had a number of short- and long-term consequences.